DDInter1875 DDInter1376
A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Trimetrexate {u} (Compound) resembles {v} (Compound) Trimethoprim
Trimetrexate {u} (Compound) binds {v} (Gene) DHFR
Trimetrexate {u} (Compound) causes {v} (Side Effect) Hyponatraemia
Trimetrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fluconazole
Trimetrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Trimetrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Trimetrexate {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Trimetrexate {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Trimetrexate (Compound) resembles Trimethoprim (Compound)
Trimetrexate (Compound) binds DHFR (Gene)
Trimetrexate (Compound) causes Hyponatraemia (Side Effect)
Trimetrexate may cause a minor interaction that can limit clinical effects when taken with Fluconazole
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Trimetrexate may lead to a major life threatening interaction when taken with Mipomersen
Trimetrexate may lead to a major life threatening interaction when taken with Clozapine